Bessemer Group
SNDX icon

Bessemer Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Bessemer Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-49
Closed – – 2708
2025
Q2 		$0 Hold
49
– – ﹤0.01% 2622
2025
Q1 		$1K Buy
+49
New +$691 ﹤0.01% 2394
2024
Q4 		– Sell
-65
Closed -$1K – 2672
2024
Q3 		$1K Buy
+65
New +$1.34K ﹤0.01% 2535

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Bessemer Group's SNDX Position: Q3 2025 in Review

Bessemer Group sold out of Syndax Pharmaceuticals (SNDX) in Q3 2025, closing a stake of 49 shares.

Bessemer Group first reported a position in SNDX in Q3 2024 and held it in 3 quarters. The position peaked at $1K in Q1 2025. 227 funds tracked by Wall St. Rank hold SNDX as of Q3 2025.

  • Bessemer Group reported no remaining Syndax Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Bessemer Group sold 49 Syndax Pharmaceuticals shares in Q3 2025.
  • Bessemer Group first reported a position in Syndax Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Bessemer Group's Syndax Pharmaceuticals position peaked at $1K in Q1 2025.
  • 227 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2025.

Based on Bessemer Group's 13F filing for Q3 2025, filed 5 Nov 2025.